Has Steven Ko, MD received payments from drug or device companies?

Yes. Drug and device makers reported $682 in general payments to Steven Ko, MD across 34 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Steven Ko, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Steven Ko, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Steven Ko, MD

Rheumatology · Fort Wayne, INNPI 1992771257

Payments from drug & device makers

$682in general payments, 2019–2025

Across 34 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$241
Pfizer$122
Aurinia Pharma U.S., Inc.$111
Novartis$107
AbbVie$31
Octapharma USA, Inc.$22
plus $49 from 3 others

What the payments were for

Food & beverage$55081%
Education$13219%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	13	$241
Pfizer	8	$122
Aurinia Pharma U.S., Inc.	1	$111
Novartis	6	$107
AbbVie	2	$31
Octapharma USA, Inc.	1	$22
Radius Health, Inc.	1	$19
E.r. Squibb & Sons, L.L.C.	1	$15
AstraZeneca	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LUPKYNIS$111

How this compares

$682 in reported general payments places this provider in the 25th percentile of 106 rheumatology providers in Indiana.

See all rheumatology providers in Indiana →

Medicare billing

Part B allowed, 2024

$1,580,363

Medicare patients

436

Services billed

93,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Enbrel SureclickEtanercept	75	$634,666
Humira(Cf) PenAdalimumab	53	$457,137
EnbrelEtanercept	46	$332,404
Humira(Cf)Adalimumab	24	$239,866
Taltz SyringeIxekizumab	12	$81,657
BenlystaBelimumab	15	$72,638
KineretAnakinra	12	$68,139
ForteoTeriparatide	13	$55,799
KevzaraSarilumab	12	$51,280
ProliaDenosumab	12	$21,352
Hydroxychloroquine Sulfate	505	$18,183
MethotrexateMethotrexate Sodium	643	$12,974
Leflunomide	171	$8,806
Mycophenolate Mofetil	55	$7,531
Sulfasalazine DrSulfasalazine	117	$4,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenEnbrel, Prolia	$241	$353,75758 claims
AbbVieHumira(Cf)	$31	$239,86624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 106 rheumatology providers in Indiana.

Other rheumatology in Fort Wayne

Nina RamessarFort Wayne$75K
Anil RaoFort Wayne$7K
Karen RingwaldFort Wayne$3K
Steven BehrendsenFort Wayne$2K
Moges SisayEvansville$1.8M
David BattIndianapolis$577K
Kathleen ThomasNoblesville$511K
Keith ReichDyer$193K
Douglas SmithIndianapolis$147K
Ahmad SalahMerrillville$139K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →